Skip to main content
Delfa

← Trials/Trial dossier/NCT01547169

SNIFF-LONG 21

CompletedPhase 2

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days

Asset

Insulin detemir

Listed sites

1

Recruiting sites

-

Enrollment

60

actual

Study population

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Key I/E criterion

•Alzheimer's disease

Primary endpoint

•Verbal Memory Composite

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Nih2P50AG005136-27
Org study ID39683-A
NCT IDNCT01547169

Timeline

Milestones

Study start2011-03 (month precision)
Study first posted2012-03-07estimated
Primary completion2012-12actual (month precision)
Study completion2012-12actual (month precision)
Last update posted2012-12-18estimated

Assets

Drug assets

Insulin detemir

Study populations

Who this study enrolls

Alzheimer’s diseaseMCI / preclinical Alzheimer’s

Eligibility

Who can enroll

Minimum age50 Years
Maximum age89 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Age 50-89
•Diagnosed with mild cognitive impairment, or mild/moderate AD

Exclusion criteria

•Excessively high or low blood pressure, heart rate
•BMI greater than 34
•Pre-existing diabetes not controlled by exercise
•Previous/current use of insulin
•Significant elevations in lipids, liver enzymes
•Menstrual period within the last 12 months
•Significant neurological or medical disorder (other than AD)
•Significant use of nasal decongestants
•Current use of anti-psychotic, anti-convulsive, anxiolytic, glucocorticoids, or sedative medications

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Memory
2
Executive function / language
2
Function / daily living
1
Amyloid biomarkers
1
Other (unclassified)
1

Memory

2 endpoints
Primary/protocol endpoint

Verbal Memory Composite

Time frame:Change from Baseline in Verbal Memory at 3 Weeks

descriptive

Secondary/protocol endpoint

Neuropsychological Tests of Visual Working Memory

Time frame:Change from Baseline in Visual Working Memory at 3 Weeks

descriptive

Executive function / language

2 endpoints
Secondary/protocol endpoint

Neuropsychological Test of Executive Function 1

Time frame:Change from Baseline in Executive Functioning at 3 Weeks

descriptive

Secondary/protocol endpoint

Neuropsychological Test of Executive Functioning 2

Time frame:Change from Baseline in Executive Functioning at 3 Weeks

descriptive

Function / daily living

1 endpoint
Secondary/protocol endpoint

Functional Ability

Time frame:Change from Baseline in Functional Ability at 3 Weeks

descriptive

Amyloid biomarkers

1 endpoint
Secondary/protocol endpoint

Plasma biomarkers of AD

Time frame:Change from Baseline in Plasma Biomarkers at 3 Weeks

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Glucose Tolerance

Time frame:Change from Baseline in Glucose Tolerance at 3 Weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.